RNS® System Epilepsy PAS
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||RNS® System Post-Approval Study in Epilepsy|
- SAE rate [ Time Frame: Implant through 5 years post-implant ]Calculate annual SAE rates over time in the entire subject population as well as within subpopulations.
- Neurosurgeon experience [ Time Frame: Implant through 41 days post-implant ]Demonstrate there is no difference in safety in 6-week perioperative period based on the experience of NeuroPace qualified and trained implanting physicians.
- Physician experience [ Time Frame: Implant through 1 year post-implant ]Demonstrate there is no difference in safety 1 year post-implant based on experience of NeuroPace qualified and trained treating physicians and Comprehensive Epilepsy Centers.
- Product use - surgical proceduresPresent the incidence and number of AEs related to surgical procedures associated with implant, explant, reimplantation, and revision of the neurostimulator and lead(s).
- AutopsyPresent data from autopsies obtained from any patient implanted with neurostimulator/leads.
- Median percentage reduction in disabling seizure [ Time Frame: Pre-implant (retrospective data) compared to 30 to 36 months post-implant ]Demonstrate that the median percentage reduction in disabling seizures over time in the entire subject population is comparable to the median percentage reduction in disabling seizures over time in the LTT study. Characterize the median percentage reduction in disabling seizures over time within subpopulations.
- Neurostimulator programming [ Time Frame: Through 5 years post-implant ]Demonstrate that stimulation programming classes have similar effects on the overall seizure frequency.
- Seizure worsening [ Time Frame: 6 months post-implant through 36 months post-implant ]Demonstrate that there is not a worsening in disabling seizures over time in the entire subject population. Assess the sustained effect on disabling seizure frequency over time within subpopulations.
- Neurostimulator programming [ Time Frame: Implant through 5 years post-implant ]Characterize the effects of stimulation programming classes on the overall 5-year rate of SAEs and device-related non-serious AEs.
- Neurostimulator battery longevityCharacterize the clinically observed battery longevity over time and in relation to therapy load in patients treated with the RNS System.
|Study Start Date:||April 2015|
|Estimated Study Completion Date:||May 2023|
|Estimated Primary Completion Date:||May 2023 (Final data collection date for primary outcome measure)|
A group of subjects with the RNS System implanted who elect to continue to receive RNS System responsive stimulation for the long term.
Device: RNS System
The RNS System provides closed loop responsive brain stimulation. In response to detection of previously identified electrocorticographic activity, the neurostimulator delivers stimulation to the seizure foci by way of the leads to interrupt the activity before the patient experiences clinical seizures. The typical patient is treated with a cumulative total of 5 minutes of stimulation a day.
NeuroPace, Inc. is sponsoring a post-approval study (PAS) of the RNS System device. The RNS System is the first FDA-approved closed loop responsive neurostimulator designed to reduce the frequency of seizures in individuals with partial onset seizures.
The RNS System Epilepsy PAS is a 5 year, non-randomized, open-label, multi-center prospective observational study. Data regarding safety and efficacy are collected at enrollment and periodically throughout the 5-year study.
The study is designed to assess the long-term safety and effectiveness of the RNS System as an adjunctive therapy in reducing the frequency of seizures in individuals 18 years of age or older with partial onset seizures who have undergone diagnostic testing that localized no more than 2 epileptogenic foci, are refractory to two or more antiepileptic medications, and currently have frequent and disabling seizures (motor partial seizures, complex partial seizures and/or secondarily generalized seizures).
Data from the RNS System Epilepsy PAS will be used to calculate long-term SAE rates, median percent change in seizure frequency (from pre-implant retrospective data), as well as other safety and effectiveness endpoints.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02403843
|United States, Alabama|
|University of Alabama, Birmingham|
|Birmingham, Alabama, United States, 35294|
|United States, California|
|California Pacific Medical Center|
|San Francisco, California, United States, 94115|
|University of California, San Francisco|
|San Francisco, California, United States, 94143|
|United States, Colorado|
|University of Colorado Denver|
|Aurora, Colorado, United States, 80045|
|United States, Georgia|
|Atlanta, Georgia, United States, 30322|
|United States, Illinois|
|Rush University Medical Center|
|Chicago, Illinois, United States, 60612|
|United States, Indiana|
|Indianapolis, Indiana, United States, 46202|
|United States, Kentucky|
|University of Kentucky|
|Lexington, Kentucky, United States, 40506|
|United States, Massachusetts|
|Massachusetts General Hospital|
|Boston, Massachusetts, United States, 02114|
|United States, Michigan|
|Grand Rapids, Michigan, United States, 49503|
|United States, New Hampshire|
|Dartmouth-Hitchcock Medical Cente|
|Lebanon, New Hampshire, United States, 03756|
|United States, New York|
|NYU Langone Medical Center|
|New York, New York, United States, 10016|
|United States, North Carolina|
|University of North Carolina at Chapel Hill|
|Chapel Hill, North Carolina, United States, 27514|
|United States, Pennsylvania|
|University of Pennsylvania|
|Philadelphia, Pennsylvania, United States, 19104|
|Thomas Jefferson University|
|Philadelphia, Pennsylvania, United States, 19107|
|United States, Tennessee|
|Le Bonheur Children's Hospital|
|Memphis, Tennessee, United States, 38105|
|Nashville, Tennessee, United States, 37232|
|United States, Washington|
|Swedish Health Services|
|Seattle, Washington, United States, 98122|
|Study Director:||Martha J Morrell, MD||NeuroPace, Inc.|